Many cancer medications fail to effectively target the most commonly mutated cancer genes in humans, called RAS. Now, scientists have uncovered details into how normal RAS interacts with mutated RAS ...
K.W. Wood, C. Sarnecki, T.M. Roberts, J. Blenis, "ras mediates nerve growth factor receptor modulation of three signal- transducing protein kinases: MAP kinase, Raf-1 ...
Despite the crucial role of RAF kinases in cell signaling and disease, we still lack a complete understanding of their regulation. Heterodimerization of RAF kinases as well as dephosphorylation of a ...
Many cancer medications fail to effectively target the most commonly mutated cancer genes in humans, called RAS. Now, Salk Professor Geoffrey Wahl and a team of scientists have uncovered details into ...
Highlights: The study examines anti-RAS activity in a series of RAS inhibitors with a predicted unique interaction region. The compounds, in development at Qualigen Therapeutics, bind wild type KRAS ...
LA JOLLA--(May 18, 2020) Many cancer medications fail to effectively target the most commonly mutated cancer genes in humans, called RAS. Now, Salk Professor Geoffrey Wahl and a team of scientists ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results